PARP1 and cancer: Thus, we investigated if combining CTPI2 treatment with the PARP-inhibitor (PARPi) PJ34 or the DNA-PKcs inhibitor (DNA-PKi) NU7447 would sensitize irradiated lung (A549, NCI-H460) and glioblastoma (U87-MG and T98G) cancer cell lines to radiation treatment.